Asset Details
Do you wish to reserve the book?
Progress in the Treatment of Small Intestine Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Progress in the Treatment of Small Intestine Cancer
Do you wish to request the book?
Progress in the Treatment of Small Intestine Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Progress in the Treatment of Small Intestine Cancer
2023
Overview
Opinion statement
Small intestine cancer is rare, accounting for approximately 3% of all gastrointestinal malignancies. The most common histological subtypes include adenocarcinoma, neuroendocrine tumours (NETs) and gastrointestinal stromal tumours (GISTs). In localised disease, surgery remains the mainstay of treatment and the best approach to improve survival. Current treatment for small intestine adenocarcinoma (SIA) is extrapolated from small studies and data from colorectal cancer (CRC). There is limited evidence to guide therapy in the adjuvant setting. However, there are small phase II studies in the advanced setting providing evidence for the role of chemotherapy and immunotherapy. There is also limited evidence assessing the efficacy of targeted therapies. Small intestine NETs are rare, with evidence for somatostatin analogue therapy, particularly in the low to intermediate-grade well-differentiated tumours. Poorly differentiated NETs are generally managed with chemotherapy but have worse outcomes compared with well-differentiated NETs. The management of small intestine GISTs is largely targeting KIT mutations with imatinib. Recent trials have provided evidence for effective therapies in imatinib-resistant tumours and the potential role of immunotherapy. The aim of this article was to review the evidence for the current management and recent advances in the management of small intestine adenocarcinoma, NETs and GISTs.
Publisher
Springer US,Springer Nature B.V
Subject
/ Adenocarcinoma - drug therapy
/ Antineoplastic Agents - therapeutic use
/ Gastrointestinal Stromal Tumors - diagnosis
/ Gastrointestinal Stromal Tumors - etiology
/ Gastrointestinal Stromal Tumors - therapy
/ Humans
/ Imatinib
/ Imatinib Mesylate - therapeutic use
/ Intestinal Neoplasms - diagnosis
/ Intestinal Neoplasms - etiology
/ Intestinal Neoplasms - therapy
/ Intestine, Small - pathology
/ Lower Gastrointestinal Cancers (AB Benson
/ Medicine
/ Mutation
/ Neuroendocrine Tumors - therapy
/ Oncology
/ Topical Collection on Lower Gastrointestinal Cancers
/ Tumors
